Opendata, web and dolomites

EPIGEN

EPIGEN: A New Predictive Response Test for Non Small Cells Lung Cancer Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EPIGEN" data sheet

The following table provides information about the project.

Coordinator
IGEN BIOTECH SL 

Organization address
address: CALLE GUSTAVO FERNANDEZ BALVUENA 11
city: MADRID
postcode: 28002
website: www.igenbiotech.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.igenbiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IGEN BIOTECH SL ES (MADRID) coordinator 50˙000.00

Map

 Project objective

EPIGEN test is a ready-to-use tool capable to lead the oncologist to the best Non Smal Cell Lung Cancer treatment, the most common subtype of lung cancer (80% of cases). The standar treatments to combat NSCLC are both chemo- and radiotherapy, but many patients (up to 65%) presents resistance, and currently there is not any tool available for the clinician to predict it. The EPIGEN test will allow the clinician a patient stratification in terms of the patient susceptibility to radio- and chemotherapy, and therefore lead for a personalyzed prescription. The EPIGEN test tecnology is based on the determination of the methylation percentage of the epigenetic biomarker IGFBP-3 in the patient tumor samples. The methylation percentage of IGFBP-3 is determined by using qMS-PCR (quantitative methylation specific polymerase chain) tecnique, a well known and extended biochemistry tecnique. The methylation percentage provided by using the EPIGEN test protocol and reagents in the qMS-PCR tecnique will lead the clinician for the optimal NSCLC treatment, avoiding the possible patient resistance to chemo and radiotharapy, and therefore unnecesary side effects and costly therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIGEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIGEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More